Biology / Biotechnology Technology Offers

Consejo Superior de Investigaciones Científicas posted this:

Transphagocytic T cells as anti cancer immunotherapy CSIC´s research group, in collaboration with scientists from the Centre of Molecular Biology “Severo Ochoa” (CBMSO-CSIC), the Autónoma University of Madrid and the Health Research Institute of the “La Princesa” University Hospital, developed a new method for anti-cancer immunotherapy based on transphagocytic lymphocytes (tiCD4+ T cells) Companies interested in a patent license or investors for creation of a start-up are being sought. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Overcoming resistance to Beta-lactam antibiotics in Bacterial species CSIC and the University of Würzburg have developed a new method to eliminate antibiotic-resistant bacterial infections using classical antibiotics previously discarded due the occurrence of antibiotic resistance. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Biocompatible self-generating cell stimulator CSIC through the Instituto de Microelectrónica de Barcelona - Centro Nacional de Microelectrónica, has developed a device based on nanogenerators for electrical cells stimulation without the need of electrodes or bulky devices. The device is biocompatible and, among its multiple applications, is able to actuate in medical prostheses as enhancer of cellular growth and proliferation, which permits an early lesion recovery (such as a fracture or wound). Industrial partners dedicated to the development of medical devices for cells stimulation, in particular, focused onto therapeutic treatments of non-healing wounds, are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

New treatment for epidermolysis bullosa and fibrosis CSIC, Carlos III University of Madrid and CIEMAT have repositioned drugs that stimulate endogline expression and modulate the TGF-β route for a new clinical use in the treatment of fibrosis, such as epidermolysis bullosa (EB). EB includes a heterogeneous group of rare hereditary diseases of the skin in which in its infantile incidence the patients are known as "butterfly children". It is a new therapy for a rare pathology, with potential in a wide spectrum of fibrosis, which would improve the possibilities of treatment of patients, improving their quality of life. Industrial partners from the pharmaceutical industry are being sought for its development in a wide variety of fibrotic pathologies through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Control of neurodegenerative diseases with benzothiazole-benzamide derivatives CSIC has developed a group of heterocyclic compounds derived from a privileged structural nucleus with the capacity to inhibit the LRRK2 enzyme. This inhibitory activity makes them useful in the treatment of neurodegenerative diseases affected by this enzyme, among which Parkinson's disease and Alzheimer's disease stand out. Pharmaceutical companies interested in the development and commercialization of these compounds under a patent license are sought. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Kits for cell culture based on hydrogel coatings CSIC and Complutense University of Madrid have developed new kits for cell culture based on cytocompatible hydrogels coated onto stiff substrates. Due to the excellent adhesion of the hydrogel to these substrates is possible to have mechanically robust platforms, easy to handle as required in a cellular biology laboratory. These new kits have been successfully tested showing an excellent cellular proliferation on the surface of the hydrogel. Besides, this technology allows the detachment of a cell monolayer without the need of chemical or biological agents preserving the viability of cell harvesting. Industrial partners from the biotechnology with expertise in cell culture are being sought to collaborate through a patent license agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Compounds for the treatment and prevention of immune-mediated inflammatory diseases CSIC and the University of Athens have found that secoiridoids, such as oleacein and oleocanthal, are useful to prevent or treat illnesses that results in immune-mediated gastrointestinal alterations. A company dealing with pharmaceutical or nutraceutical compositions is sought for licensing agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Biotechnological production of 11α hydroxylated steroids using recombinant bacteria.CSIC has developed a procedure for the biotechnological production of 11α hydroxylated steroids by generating and subsequent use of recombinant bacteria. These recombinant bacteria allow to perform microbial biotransformation processes that result in 11αhydroxylated steroid compounds from raw materials such as phytosterols and intermediate products efficiently and economically. These compounds have numerous applications in pharmacology. Companies are sought for implementing and commercializing the new technology under patent license agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Compounds for the treatment of optic neuritis CSIC and the University of Athens have found that secoiridoids, such as oleacein and oleocanthal, are useful to prevent or treat neuropathies that conduct to optic nerve injury, such as optic neuritis. A company dealing with pharmaceutical or nutraceutical compositions for ophtalmic applications is sought for licensing agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Peptide for cancer control linked to IL13R CSIC has developed a peptide capable of inhibiting the signaling of IL-13 mediated by IL13Rα2. This peptide alone or within a nanoparticle or virus-like particles can be used in a pharmaceutical composition for the treatment of pathologies in which IL13Rα2 is overexpressed. This composition would be useful in the treatment and control of metastasis of colon cancer and other tumors (i.e glioblastoma), as well as in other pathologies such as asthma, atopic dermatitis or fibrosis. Industrial partners are being sought to develop and commercialized the products through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Piperidine derivatives for the control of Parkinson's and Alzheimer's CSIC has synthesized a series of piperidine derivatives that are capable of inhibiting the activity of the enzyme phosphodiesterase-8 (PDE8). This inhibitory activity makes them useful for the treatment of neurodegenerative diseases in which this enzyme is overexpressed. The compounds developed are, therefore, a new therapeutic alternative for Alzheimer's disease, and Parkinson, among others. Industrial partners from pharmaceutical industry are being sought to develop and commercialized the compounds through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Regulatory compounds of synaptic transmission for the treatment of neurological diseases The CSIC and IRYCIS (Ramón y Cajal Institute for Health Research) have developed a group of compounds. These compounds have the ability to regulate the number of synapses that are formed between neurons, as well as the probability that neurotransmitters are released from these, because they have the capability of modulate the interactions that take place between the regulatory proteins NCS-1 and Ric8a that regulate these two independent processes. Due to these neuromodulatory properties, these compounds are useful for the treatment of neurological diseases as Alzheimer's disease, Huntington or Parkinson's diseases among others. Industrial partners from the ophthalmic or pharmaceutical industry are being sought to collaborate through a patent license agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Antibiotics to treat diseases caused by Helicobacter CSIC, the University of Zaragoza, Institute Pasteur, IISA and ARAID have developed chemical derivatives that act selectively against the bacterium Helicobacter pylori, managing to reduce the bacterial load and even eradicate gastric infections caused by it. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Use of immobilized enzymes in the synthesis of biodiesel CSIC has developed a process for the enzymatic synthesis of alkyl esters of long chain fatty acids in the presence of an alcohol and an enzymatic preparation with a sterol esterase/lipase covalently immobilized on magnetic particles functionalized on its surface. The process increases the yield of the synthesis of alkyl esters, and allows recovery of the catalyst. The synthesized compounds can be used as biofuel. Industrial partners are being sought to use the technology through a patent licence agreement. An offer for Patent Licensing

Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante

New compound to successfully treat degenerative diseases of the retina The research group "Neurobiología del sistema visual y terapia de enfermedades neurodegenerativas" of the University of Alicante has discovered the use of the compound 3-(2-isothiocyanatethyl)-5-methoxy-1H-indol, and its pharmaceutically acceptable salts, for the preventive or therapeutic treatment of degenerative diseases of the retina, such as: pigmentary retinosis, diabetic retinopathy, glaucoma or age-related macular degeneration. This compound has demonstrated, in vitro and in vivo, its neuroprotective capacity in various models under laboratory conditions. This compound is characterized by a 20% increase in neuronal survival, a 35% increase in visual acuity, and a 15% increase in contrast sensitivity. Therefore, it has very promising properties that could position it as the first effective treatment against degenerative diseases of the retina. We are looking for companies interested in acquiring this patent for commercial exploitation.

Biology / Biotechnology Technology Offers

Innovation Resources

Sitemaps

Support

Company

Top Posts Categories

Recognitions

Biology / Biotechnology Technology Offers

Recognitions

Follow us